Glucose Analysis Tubes Market

Glucose Analysis Tubes Market Outlook (2023-2033)

The global revenue from the glucose analysis tubes market stands at US$ 426.8 Mn in 2022, with the global market expected to grow at a CAGR of 5.9% to reach a valuation of approximately US$ 791.8 Mn by the end of 2033.

As assessed by Persistence Market Research, PET/plastic products hold a market share of around 84.6% in the global market, in 2022. Overall, glucose analysis tubes market sales account for approximately 23.4% revenue share in the global blood collection tubes market, which was valued at around US$ 1.8 Bn in 2022.

Sales Analysis of Glucose Analysis Tubes Market from 2016 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 3.9% in the last 6 years from 2016 to 2022.

Around the world, a sizable portion of the population has diabetes or pre-diabetic disorders. This is largely caused by ongoing changes in people's lifestyles, such as poor eating habits, disrupted sleep patterns, and a lack of physical activity and exercise. Diabetes risk can be decreased by regularly checking blood glucose levels and adopting healthy lifestyle and eating practises.

The prevalence of diabetes is rising globally, which is driving up demand for glucose analysis tubes. The substantial changes in people's lifestyles, such as irregular sleep patterns and bad eating patterns, are to blame for the rise in diabetes.

Additionally, regular blood glucose monitoring is becoming more widely known. People now place a high value on their physical well-being. Manufacturers are also concentrating on developing cutting-edge devices that support in regulating and monitoring blood glucose levels.

Sodium fluoride contributed for a sizable portion of the revenue in 2022. This is due to the instability of glucose in whole blood. Fluoride tubes are therefore adopted to suppress glycolysis, especially when highly specific glucose readings are necessary.

Diabetes is estimated to affect 537 Mn individuals (20-79 years old) by 2021, according to the WHO. The world will have 643 Mn diabetics globally by 2030, and 783 Mn by 2045.

The expansion of the geriatric population and the rising need for blood transfusions to treat various haematological conditions that call for the use of EDTA tubes are further boosting the market's growth in the Asia-Pacific region.

Agreements, collaborations, and partnerships have emerged as crucial growth strategies being pursued by industry players, after the development of innovative products and approvals. Key stakeholders are enhancing their current product portfolios and extending their geographic reach by concentrating on these initiatives.

The global market is thus likely to show high growth over the coming years at a CAGR of 5.9% and reach a global market size of US$ 791.8 Mn by 2033.

How Can the Global Glucose Analysis Tubes Market Grow?

“Availability of Guidelines on Sample Collection and Storage, and Novel Product Development”

The diagnosis of diabetes and impaired fasting glucose depends on accurate determination of plasma glucose. The major element of obstruction for plasma glucose determination is the drop in glucose in blood samples before they are analysed attributable to ex-vivo glycolysis, especially if that analysis is delayed, if sample is not stored in a refrigerator appropriately, and it is not centrifuged right away after venipuncture.

For reliable diabetes diagnosis and accurate results, in vitro glycolysis must be stopped. Several inhibitors, including sodium or lithium iodoacetate, sodium fluoride (NaF), d-mannose, and blood acidification, have been employed as additives in the blood collection tubes to inhibit in vitro glycolysis.

The enzyme enolase, that catalyses a downstream step of glycolysis, is inhibited by NaF, a routinely used but ineffective agent. Until all the substrates for the upstream enzymes are used up, other upstream step enzymes continue to be active, delaying the inhibition of glycolysis by around 4 hours.

Contrarily, it has been apparent that the upstream enzymes of the glycolytic cascade are promptly inhibited when whole blood is acidified with citrate buffer.

The National Academy of Clinical Biochemistry's (NACB) 2011 recommendations for blood collection and preservation for testing in the laboratory for the clinical management of diabetes include reducing the impact of glycolysis on plasma glucose measurement by placing the sample tubes immediately in an ice-water slurry and isolating plasma from cells within 30 minutes of blood withdrawal.

The usage of tubes comprising inhibitors, such as sodium fluoride with citrate buffer, is advised in order to inhibit early glycolysis because the ideal procedure of freezing and cold processing samples taken under 30 minutes is not feasible in routine analysis.

With the presence of international guidelines on blood sample collection and storage, as well as the rising research on glycolysis inhibitors in novel analysis tubes, the market is set to gain lucrative growth over the forecasted years.

Can the Glucose Analysis Tubes Market Growth Be Affected in Any Way?

“Lack of Trained Professionals and High Cost of Care”

It takes trained specialists to draw blood using a glucose analysis tube. Lack of qualified specialists can cause a number of issues during the technique, including erroneous identification, the use of the unsuitable tubes, and inadequate sample size.

The procedure's invasiveness is another drawback. Currently, minimally invasive or non-invasive glucose analysis devices such as test strips are more appealing to consumers. These strips are less invasive and unpleasant. Therefore, the availability of these alternatives may limit the growth of the market in the next years.

One of the significant restrictions of the global industry is the excessive cost connected with test strips. As a diabetic patient needs four to five strips each day for effective blood glucose monitoring, this raises the overall cost of care. As a result, the vast majority of patients are switching to the less expensive nonexclusive strips.

Country-wise Insights

Why is the U.S. Market Booming?

“Growing Incidence of Lifestyle Disorders and Enhanced Healthcare Facilities”

The U.S. accounted for around 87.3% market share in the North America market in 2022. Lifestyle modifications and unhealthy eating habits, as well as the presence of multiple manufacturers in the U.S., are factors that are driving the market's expansion in North America. These factors include the increased incidence of blood disorders and the prevalence of lifestyle diseases, as well as superior healthcare facilities.

Will Russia Be a Lucrative Market for Glucose Analysis Tubes?

“Growing Incidence of Diabetic Population”

Russia held around 20.5% market share of the Europe market in 2022. Diabetes affects a sizable section of the population in Russia. Additionally, the presence of companies manufacturing glucose analysis tubes makes these products more widely available in the nation.

Concerning the number of patients with diabetes mellitus between the ages of 20 and 79, Russia is ranked sixth in the world by the Roscongress Foundation.

Additionally, the death rate for patients with diabetes mellitus increased by 22% during COVID-19. Due to the high prevalence of diabetes in the nation, there are more opportunities for analysis tubes for glucose monitoring to be used, which would boost sales in the global market over the projection period.

How is China Emerging as a Prominent Market?

“Large Geriatric Population and Presence of Local Manufacturers”

China held a market share of about 84.7% of the East Asia market in 2022. The growing ageing population in China has propelled the demand for blood sample analysis, thus propelling the overall market. Moreover, with rising age, the incidence of chronic illness increases. There are several manufacturers locally supplying sample collection tubes for glucose monitoring.

Moreover, with the advent of the global COVID-19 pandemic, sample collection is also associated with considerations to prevent infection proliferation. These guidelines will provide product manufacturers with opportunities to expand into the regional market with products tailored as per guidelines for infection prevention.

Category-wise Insights

Which Product is Driving Demand within the Global Market?

“Sample Preservation Efficiency”

The sodium fluoride segment held around 41.8% share of the total market in 2022. Tubes containing fluoride are used to limit glycolysis, particularly when extremely precise glucose measurements are desired. One of the analytes that is measured in laboratories the most commonly is glucose. If the process of separating plasma from cell components takes more than a few hours, the NaF tubes are helpful.

To ensure sample integrity, the advantages of sodium fluoride tubes for the storage of blood samples is effective for around 3 hours from venipuncture. This is particularly beneficial in a laboratory setup with a vast sample size, thus promoting the segment as a leading product within the global market.

Which Material is Largely Preferred in Terms of Manufacturing within the Global Market?

“Durability of Products”

PET/plastic products hold a share of around 84.6% within the global market in 2022. PET, a material frequently used to manufacture analysis tubes for blood glucose monitoring, is indestructible and can sustain a vacuum for an extended period of time. Another widely used plastic is PP, which has a lower water permeability and may retain the amount and concentration of liquid anticoagulant.

The inside PP layer prevents citrate solution evaporation, while the outside PET layer is more transparent and makes it easier to see the tube fill levels. As a result, PET tubes feature double-walls to reduce evaporation, particularly for coagulation-based tests.

Which End User Offers the Market a Profitable Outlook?

“Availability of Adequate Equipment”

Diagnostic laboratories held a larger share of about 46.3% in 2022. With the rising number of patients with chronic diseases, as well as a growing ageing population, the market has gained traction in terms of growth, and will continue the same over the forecasted years. Diagnostic laboratories play a major role in sample assessment and processing. Moreover, with the availability of equipment for storage of blood samples, as well as the in-house processing of the same, this segment holds a greater market share within the global market.

Competition Landscape

Key firms are concentrating on new product manufacturing and expansion in developing regions. Key manufacturers are bolstering market growth through expansion strategies, new product releases and approvals, agreements, partnerships, and collaborations, as well as enhanced distribution channels like online sales.

Moreover, with the availability of reimbursement for several testing methods has provided further traction to the overall market.

Key players are enhancing their products with the introduction of tubes containing combinations of sodium fluoride and citrate buffer.

Some key instances of development include:

• Greiner Bio-One unveiled the Vacuette FC Mix Tube for glucose analysis in February 2021.
• Becton, Dickinson, and Company (BD) reformed the instructions for their BD vacutainer tubes in March 2018 as part of its quality assurance approach to secure the appropriate use of these tubes.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies manufacturing glucose analysis tubes, which are available in the full report.

Glucose Analysis Tubes Industry Report Scope

Key Segments Covered in Global Industry Research

Product:

• Sodium Fluoride
• Potassium Fluoride
• Fluoride Oxalate

Material:

• PET/Plastic
• Glass

End User:

• Diagnostic Laboratories
• Hospitals & Clinics
• Research & Academic Institutes
• Veterinary Hospitals & Clinics

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

About Author

Anu Jamwal

Senior Consultant

Anu is a Senior Consultant with over a decade of experience and has developed deep expertise in clinical diagnostics, biotechnology, animal health, healthcare IT, and pharmaceuticals, including pipeline assessment. She has authored comprehensive reports providing both global and regional competitive intelligence. She has also successfully led consulting assignments focused on business strategies, product launches, and medical census studies.

Read More →